One Molecule to Rule Them All? Five Different Anti-Aging Treatments Leave the Same Chemical Fingerprint in Mice

News
#1

NewRMillerBiorxive
NewRMillerBiorxive2752×1536 389 KB

Five mechanistically distinct longevity interventions — rapamycin, acarbose, 17α-estradiol, canagliflozin, and caloric restriction — produce partly overlapping metabolic signatures across seven mouse tissues, with the dietary antioxidant ergothioneine rising consistently in brain, plasma, and muscle. A machine-learning model can spot “treated” mice from any of the five interventions even when trained only on the other four.

Researchers have long known how to slow aging in mice — calorically restrict them, or give them one of a handful of drugs — but why these very different treatments all work has stayed murky. A team led by Richard Miller’s lab at the University of Michigan, working with the West Coast Metabolomics Center at UC Davis, asked a deceptively simple question: do these interventions, despite hitting different molecular targets, leave a shared chemical mark on the body?

To find out, they treated genetically diverse male mice with one of five validated interventions from young adulthood, then harvested seven tissues — plasma, brain, liver, muscle, kidney, and two fat depots — at one year of age, well before the animals would start dying. They fed the resulting metabolite profiles into XGBoost, a tree-based machine-learning system, and added a useful trick: running each model a thousand times to stop the rankings jumping around with random chance, a recurring headache in this kind of high-dimensional analysis.

Two things stood out. First, the models could reliably tell treated mice from untreated controls in every single tissue. More striking, a model trained on any four interventions could correctly flag mice given the fifth, unseen intervention — implying these distinct treatments share underlying metabolic changes rather than each carving its own separate path.

Second, when the team asked which individual molecules carried the most weight, the answer was mostly tissue-specific. The metabolites that mattered in muscle barely registered in liver, and so on. Only one molecule punched through across multiple tissues: ergothioneine, a fungus-derived antioxidant that mammals cannot make and must absorb from food. It rose in brain and plasma under all five interventions, and in muscle under four. Alongside it, the team saw coordinated reshuffling of fats — a shift toward longer, more flexible polyunsaturated lipids, and in muscle a rise in cardiolipin, a fat critical to mitochondrial function that normally declines with age.

The authors are careful: they don’t yet know whether ergothioneine causes any benefit or is simply a marker of altered nutrient uptake. And they haven’t yet tested whether their model can distinguish genuine longevity drugs from drugs that do nothing for lifespan — the crucial control that would prove this is an aging signature and not just a “something was given” signature. But as a proof of concept, it hints at a faster way to screen candidate anti-aging compounds: read the metabolic tea leaves at one year instead of waiting three for the animals to die.

Actionable Insights

The single translatable thread is ergothioneine — the only metabolite that rose across multiple tissues under every intervention. It is a dietary compound (richest sources: oyster, king oyster, shiitake mushrooms; lower amounts in tempeh, organ meats, some beans), so unlike the drugs studied, it is something you can actually consume. It is also available widely as a supplement.

But the effect size that matters here is not in this paper. This study shows ergothioneine rising as a correlate of treatments that extend lifespan — it does not show that taking ergothioneine extends lifespan or improves any outcome. The authors explicitly raise the possibility that elevated ergothioneine is a surrogate marker for increased gut absorption of other nutrients, not a causal agent.

Practical take-home: ergothioneine is low-risk and biologically plausible, but its benefit remains unproven; treat it as a reasonable dietary hedge, not a validated geroprotector.

Source:

Related Reading:

7 Likes
#2

Important research. Re: ergothioneine - causality indeed needs to be established, but there are studies that address this somewhat. I have been taking ergo as a supplement, though on a pretty careful pulse schedule (1 mo on + 1-week x 12 + 1mo etc.), because the literature is encouraging - example:

Ergothioneine promotes longevity and healthy aging in male mice

3 Likes
#3

To summarize that paper you just linked to:

The Mushroom Amino Acid That Helped Male Mice Live Longer — But Started From a Sick Baseline

Daily low-dose ergothioneine in drinking water extended male mouse lifespan by ~21% on average and blunted frailty, kidney aging, and memory loss — but the control mice were strikingly short-lived, which inflates how impressive the headline number looks.

Ergothioneine (ERGO) is a sulfur-containing amino acid you can’t make yourself. You get it from food — mushrooms are the richest source — and it’s hoovered into your cells by a dedicated transporter (OCTN1) that concentrates it in tissues under oxidative stress. Bruce Ames famously nominated it a “longevity vitamin,” a nutrient that isn’t acutely essential but whose chronic absence quietly accelerates aging. This paper is the first serious attempt to test that idea on the ultimate endpoint in a mammal: does feeding ERGO make mice live longer and age better?

The answer, on its face, is yes. A Japanese team gave male mice roughly 4–5 mg/kg/day of ERGO in their water from young adulthood until natural death. Treated mice lived a median 16% longer, an average 21% longer, and the age by which 90% had died rose 29%. The effect replicated in the worm C. elegans, where the highest dose stretched lifespan ~31%. ERGO mice also stayed physically robust longer — less age-related weight and fat loss, faster movement velocities in old age — and held onto their memory, scoring higher on object-recognition tests at both middle and old age.

Underneath the survival curve, ERGO touched nearly every aging system the authors looked at. It lowered liver lipid peroxidation, suppressed the inflammatory-aging chemokine CXCL9, preserved the longevity-associated enzyme SIRT6, and tamped down the senescence marker p16. It scrubbed a panel of kidney-aging markers (creatinine, urea, SDMA, ADMA) back toward youthful levels. In the brain, it preserved new-neuron birth in the hippocampus, nudged immune microglia from an inflammatory to a reparative state, and reduced toxic TDP-43 protein clumping.

Here’s the catch, and the authors deserve credit for admitting it. Their control mice averaged just 590 days. Normal lab male C57BL/6J mice average ~878 days. So the controls weren’t aging normally — they were dying young, plausibly because the special low-ergothioneine diet (and its high fat content) was itself harmful. Viewed that way, ERGO may not be a longevity drug so much as a correction for a deficiency the experiment created. The signal is real and biologically broad. The magnitude is almost certainly overstated.

Actionable Insights

The mouse dose translates to a realistic human supplement. Using standard allometric scaling (mouse-to-human Km correction, ×0.081), 4–5 mg/kg/day in mice maps to roughly 0.33–0.41 mg/kg/day, or about 23–28 mg/day for a 70 kg adult [Confidence: High for the arithmetic; Low that the lifespan benefit transfers]. That dose is squarely in the range of existing commercial ERGO products and is easily reachable through diet — a few servings of mushrooms weekly.

The honest take-home: the strongest, most replicated human-relevant signals here are not lifespan but the biomarker and frailty effects, several of which align with existing human epidemiology (low plasma ERGO predicts dementia, cardiovascular mortality, and frailty). The plausible real-world magnitude for a well-nourished person is modest — you are likely topping up a system rather than supercharging it. The 21% lifespan number should not be your expected effect size; it is the effect of rescuing depleted mice. Treat ERGO as a low-risk, food-derived antioxidant/anti-inflammatory with decent mechanistic and observational support, not as a proven geroprotector.

Context

  • Institution: Kanazawa University (lead) with Kumamoto University
  • Country: Japan
  • Journal: GeroScience (official journal of the American Aging Association)

Impact Evaluation

GeroScience’s most recent Journal Impact Factor is 6.0 (2025), with a 5-year impact factor of 6.2, and a CiteScore of 8.3; it sits in JCR Q1. The impact score of this journal is 6.0, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal

3 Likes
#4

Absolutely. The controls were trash, which is why ergothioneine being causative has not been proven, only possibly hinted at. Much more research is needed, as so often. Nonetheless, there is enough signal there for me to take a gamble on it - essentially this is not a novel molecule but a component of the human diet, so if you don’t go overboard, I think it’s reasonably safe (assuming being careful not to take in overwhelming supraphysiological dodes).

2 Likes
#5

Certainly enough evidence to put it on my supplement list. It has little downside.

Some L-ergothioneine tidbits from Gemini Pro 3.1

What is the safe dosage? The estimated biological half-life of EGT in the human body is approximately 1 month (Tang et al., 2018).

Dosing limits and safety:

The European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA) have designated synthetic L-ergothioneine as a safe, novel food.

  • Recommended Daily Intake: Regulatory bodies and the majority of human interventional trials recommend a daily dosage of 25 to 30 mg/day for adults (Bell & Fernandes, 2023).
  • Maximum Safe Limit: The physiological safety ceiling is exceptionally high. Subchronic toxicity studies established a No Observed Adverse Effect Level (NOAEL) of 800 mg/kg of body weight per day. This upper limit vastly exceeds any practical dietary or supplemental intake, indicating an excellent safety profile."

This belies some members’ concerns about the amount of daily dosing.

How does EGT interact with mTOR?

The Brain and the “Rapamycin Paradox”

In the central nervous system, EGT has been shown to actively stimulate mTORC1.

Oxford Academic - Oxford University Press

  • Neurogenesis via mTOR: EGT exposure in neural stem cells significantly increases the phosphorylation of mTOR and its downstream positive effector, p70S6K. This localized mTORC1 activation is the primary mechanism EGT uses to increase the expression of Brain-Derived Neurotrophic Factor (BDNF) and promote new neuron differentiation.
    Oxford Academic - Oxford University Press
  • The Antagonistic Interaction: In vitro studies have demonstrated that administering rapamycin directly suppresses EGT’s ability to phosphorylate mTOR in these cells. Consequently, the presence of an mTOR inhibitor blunts EGT’s neurogenic and neuroprotective effects. This highlights a direct, antagonistic interaction in the brain when both compounds are active simultaneously.

Skeletal Muscle and Sarcopenia Defense

Preserving lean mass and preventing sarcopenia requires robust, pulsed mTORC1 activation, typically triggered by mechanical load (resistance training) and amino acid availability.

A well-documented problem in sports physiology is that high doses of “primary” antioxidants (like Vitamin C or E) taken post-exercise neutralize the reactive oxygen species (ROS) needed to trigger insulin sensitivity and subsequent mTOR activation. This effectively blunts muscle hypertrophy and training adaptations.

  • Preserving the mTOR Signal: EGT bypasses this problem because it functions largely as a secondary antioxidant. By activating the endogenous Nrf2 pathway rather than indiscriminately scavenging all free radicals, EGT clears pathological oxidative damage without silencing the early signaling required for muscle recovery.
    Frontiers
  • Satellite Cell Activation: Following exhaustive exercise, EGT-supplemented models show higher activation of muscle protein synthesis and satellite cell proliferation. It allows the mTOR pathway to function optimally in response to mechanical stress while simultaneously protecting the mitochondria from damage.
    Frontiers
  • Synergy with NAD$^+$: Recent research (published in Cell Metabolism in 2025) reveals that EGT also increases the activity of the enzyme G3P dehydrogenase (GPDH) via a process called persulfidation. This action enhances endogenous NAD$^+$ regeneration directly within muscle tissue, further supporting muscle stem cell health, vascularization, and aerobic endurance.
    NAD.com

Strategic Implications

The tissue-specific actions of EGT underscore why chronic, unmitigated mTOR suppression is suboptimal for long-term healthspan.

Tissues like the brain and skeletal muscle fundamentally require periodic mTOR activation to maintain cognitive function and defend against sarcopenia. EGT acts as a selective mTOR supporter in these high-demand tissues. Within a broader longevity regimen, this suggests that a “pulsed” strategy—where mTOR is suppressed periodically for autophagy but allowed to activate freely around resistance training or specific nutrient windows—is necessary to fully leverage EGT’s benefits without forcing metabolic pathways into conflicting directions.

How does EGT affect my resistance training schedule?

Scheduling Around Other Protocols

The lack of a timing constraint makes EGT incredibly easy to schedule within a broader longevity regimen. For example, if you are utilizing metformin, timing does matter—taking metformin too close to a workout can inhibit mitochondrial Complex I and blunt the exercise-induced mTOR spike. EGT has no such inhibitory effect, so you can take your daily 25–30 mg dose whenever it is most convenient, regardless of your gym schedule.

The Verdict

A biweekly longevity pulse is designed specifically to allow for an anabolic rebound. EGT does not blunt the autophagic clearing phase of the rapamycin peak. Instead, its steady-state presence ensures that the moment rapamycin clears, your brain and muscle tissues have optimal localized support for effective rebuilding.

Food-derived antidepressant-like compound ergothioneine promotes neuronal differentiation via activating mTORC1 and neurotrophic factor signaling in neural stem cells

Ergothioneine Improves Aerobic Performance Without Any Negative Effect on Early Muscle Recovery Signaling in Response to Acute Exercise

Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation

1 Like
#6

I am bullish on l-ergothioneine aswell. Having been on a high dose for several months now, mushrooms absolutely disgust me now which makes me consider the possibility of being overdosed. For that reason, I’ve switched over to only taking 5mg a day for maintenance.
The compound definitely needs to be tested in the ITP to validate claims made by other labs.

#7

Read the previous post. The safety factor is so high you can hardly overdose. Certainly not with 30 mg/day.

“The physiological safety ceiling is exceptionally high. Subchronic toxicity studies established a No Observed Adverse Effect Level (NOAEL) of 800 mg/kg of body weight per day. This upper limit vastly exceeds any practical dietary or supplemental intake, indicating an excellent safety profile.”

No need to take more than 30 mg/day. No additional benefits are to be had with a higher daily dose.

You will reach saturation with this dose in a few months. Of course, we might treat it like creatine and increase the dose like a loading phase, then reduce the dose to 30 mg/daily

All quotes are from Gemini Pro 3.6

“The estimated biological half-life of EGT in the human body is approximately 1 month (Tang et al., 2018)”

“Regulatory bodies and the majority of human interventional trials recommend a daily dosage of 25 to 30 mg/day for adults (Bell & Fernandes, 2023).”

No need to take more. No additional benefits are to be had with a higher daily dose.
One of the most striking features of EGT compared to other water-soluble nutraceuticals is its retention time.
The estimated biological half-life of EGT in the human body is approximately 1 month (Tang et al., 2018)

“In pharmacokinetics, it takes approximately four to five half-lives for any compound to reach its maximum stable concentration in the body (steady state).”

With a half-life of roughly one month, a daily dose of EGT will incrementally compound in your tissues for about 4 to 5 months before it levels off. Once you hit that plateau, the amount of EGT your OCTN1 transporters absorb and your kidneys retain perfectly matches the small amount your body naturally degrades or excretes each day.

If you take 30 mg daily, the mathematical model of accumulation dictates that your total bodily reservoir will eventually stabilize at roughly 1,300 mg to 1,400 mg of stored EGT, actively localized in high-stress tissues like mitochondria, erythrocytes, and skeletal muscle.

"Usually, a compounding biological half-life raises concerns about toxicity—fat-soluble vitamins (like Vitamin A or D) or heavy metals can build up to dangerous levels if dosed continually.

EGT is a rare exception because of its staggering safety profile. The total accumulated body burden of ~1.3 grams at steady state is still astronomically lower than the No Observed Adverse Effect Level (NOAEL). Because EGT does not undergo auto-oxidation or become a pro-oxidant after neutralizing a free radical, this massive cellular reservoir simply sits inertly in the mitochondria until it is needed to quench reactive oxygen species."

"Within broader longevity and bio-hacking protocols, powerful interventions often require strict cycling. For example, mTOR inhibitors like rapamycin must be dosed periodically to prevent systemic immune suppression and insulin resistance.

EGT does not require a pulsed or cycled schedule. Because it acts selectively—supporting mTOR in the brain and muscle while clearing oxidative stress without blunting hormetic signals—the biological objective is to keep tissue saturation as high as possible. Continuous, uninterrupted daily dosing is the optimal strategy to maintain that 4-to-5-month saturation plateau."

If you ingest more EGT than the transporters can actively shuttle into your mitochondria, the kidneys will simply stop reabsorbing the excess, and it will be excreted in your urine. While taking doses well above 30 mg is physiologically safe (due to the massive 800 mg/kg NOAEL ceiling), it does not translate to greater satellite cell proliferation, enhanced mTOR signaling, or better preservation of lean mass. The excess EGT is simply wasted.

Sticking to 25 to 30 mg daily ensures you hit maximum physiological saturation without pouring expensive compounds down the drain."

3 Likes
#8

My understanding is that EGT (L-ergothioneine) has an estimated plasma half-life of roughly 20–40 hours in humans.

#9

Ergothioneine is having its moment. A new study I posted.

2 Likes
#10